Barely one month after the initiation of a final-stage clinical study, the developer of China's first domestically developed mRNA COVID-19 vaccine has now been showered with cash.
Private bioventure ABOGEN INC, founded just over two years ago, has grabbed a cash injection in a huge series C funding exceeding $700m, making it one of the best funded